Filtered By:
Specialty: Endocrinology
Condition: Diabetes

This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 1416 results found since Jan 2013.

Clinical significance of skin autofluorescence for diabetic macroangiopathy and comparison with conventional markers of atherosclerosis: a cross-sectional and prospective study
ConclusionAmong diabetic macroangiopathies, SAF is a good stroke biomarker, but not for CAD and PAD.
Source: Diabetology International - November 28, 2022 Category: Endocrinology Source Type: research

Haptoglobin genotype and cerebrovascular disease incidence in type 1 diabetes
Conclusion: Despite the protective effect against vascular diabetes complications, a borderline increased risk of stroke was observed with Hp 1-1 in type 1 diabetes. This mixed Hp effect on cardiovascular risk by outcome studied merits further investigation and cautions against the universal application of preventive therapies across all Hp genotypes.
Source: Diabetes and Vascular Disease Research - August 12, 2014 Category: Endocrinology Authors: Costacou, T., Secrest, A. M., Ferrell, R. E., Orchard, T. J. Tags: Original Articles Source Type: research

Proportion of undercarboxylated osteocalcin and serum P1NP predict incidence of myocardial infarction in older men.
CONCLUSIONS: Areduced proportion of undercarboxylated osteocalcin or higherP1NPare associated with increased incidence of MI. UcOC/TOC ratio and P1NP predict risk of MI but not stroke, in a manner distinct from CTX. Further studies are needed to investigate potential mechanisms by which bone turnover markers related to metabolic risk and to collagen formation could modulate cardiovascular risk. PMID: 26308289 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - August 26, 2015 Category: Endocrinology Authors: Yeap BB, Alfonso H, Chubb SA, Byrnes E, Beilby JP, Ebeling PR, Allan CA, Schultz C, Hankey GJ, Golledge J, Flicker L, Norman PE Tags: J Clin Endocrinol Metab Source Type: research

CHA 2 DS 2 -VASc score is useful in predicting poor 12-month outcomes following myocardial infarction in diabetic patients without atrial fibrillation
Conclusions In diabetic patients with STEMI and no previous AF, median CHA2DS2-VASc score was high (4 points) and predicted 12-month death and stroke. However, it failed to predict in-hospital death and 12-month MI. CHA2DS2-VASc score had a similar discrimination performance in predicting 12-month mortality as TIMI risk score and a better discrimination performance in predicting 12-month stroke than TIMI risk score. Thus, it can serve as an additive tool in identifying high-risk patients that require aggressive management.
Source: Acta Diabetologica - June 22, 2016 Category: Endocrinology Source Type: research

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
Publication date: Available online 31 October 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Michael R McClung, Michelle L O'Donoghue, Socrates E Papapoulos, Henry Bone, Bente Langdahl, Kenneth G Saag, Ian R Reid, Douglas P Kiel, Ilaria Cavallari, Marc P Bonaca, Stephen D Wiviott, Tobias de Villiers, Xu Ling, Kurt Lippuner, Toshitaka Nakamura, Jean-Yves Reginster, Jose Adolfo Rodriguez-Portales, Christian Roux, José Zanchetta, Cristiano A F ZerbiniSummaryBackgroundOdanacatib, a cathepsin K inhibitor, reduces bone resorption while maintaining bone formation. Previous work has shown that odanacatib increases bone...
Source: The Lancet Diabetes and Endocrinology - November 2, 2019 Category: Endocrinology Source Type: research

Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
We examined the association between glucose-lowering medications and a broad range of cardiovascular outcomes, and assessed the strength of evidence for these associations.MethodsFor this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications. Cardiovascular outcomes examined included major adverse cardiovascular events, cardiovascular death, myocardial infarction, stroke, heart failure, unstable angina, and atrial fibrillation. For each meta-analysis, we estimat...
Source: The Lancet Diabetes and Endocrinology - January 30, 2020 Category: Endocrinology Source Type: research

Cardiovascular Biomarkers and Calculated Cardiovascular Risk in Orally Treated Type 2 Diabetes Patients: Is There a Link?
In conclusion, ADMA and PIGF-1 did not seem useful in stratifying CV risk while ET-1 is linked to the risk of stroke, and NT-proBNP to all CV risk estimations. [...] © Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text
Source: Hormone and Metabolic Research - July 5, 2020 Category: Endocrinology Authors: Markova, Aleksandra Boyanov, Mihail Bakalov, Deniz Kundurdjiev, Atanas Tsakova, Adelina Tags: Endocrine Care Source Type: research

Risk of early mortality and cardiovascular disease according to the presence of recently diagnosed diabetes and requirement for insulin treatment: A nationwide study
ConclusionsRecently diagnosed type 2 diabetes patients showed increased risks of incident CVDs and premature mortality, and insulin ‐treated group demonstrated an additional increase in the risks of these outcomes in adults with recently diagnosed type 2 diabetes, suggesting the need for intensified cardio‐protective interventions for adults with insulin‐treated type 2 diabetes.
Source: Journal of Diabetes Investigation - March 19, 2021 Category: Endocrinology Authors: You ‐Bin Lee, Kyungdo Han, Bongsung Kim, Min Sun Choi, Jiyun Park, Minyoung Kim, Sang‐Man Jin, Kyu Yeon Hur, Gyuri Kim, Jae Hyeon Kim Tags: Original Article Source Type: research

Plasma Free Amino Acids and Risk of Cardiovascular Disease in Chinese Patients With Type 2 Diabetes
ConclusionsElevated factor 3 composed of glutamate and tryptophan was associated with increased CVD, especially stroke in T2D in China.
Source: Frontiers in Endocrinology - April 14, 2021 Category: Endocrinology Source Type: research

The association of nine amino acids with cardiovascular events in Finnish men in a 12-year follow-up study
CONCLUSION: We identified alanine as a new amino acid associated with increased risk of CAD and glutamine as a new amino acid associated with decreased risk of ischemic stroke. We also confirmed that phenylalanine and tyrosine were associated with CAD, ischemic stroke, and CVD events.PMID:34346487 | DOI:10.1210/clinem/dgab562
Source: The Journal of Clinical Endocrinology and Metabolism - August 4, 2021 Category: Endocrinology Authors: Raimo Jauhiainen Jagadish Vangipurapu Annamaria Laakso Teemu Kuulasmaa Johanna Kuusisto Markku Laakso Source Type: research

GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
CONCLUSION: GLP-1RAs, precisely longer acting formulations, reduced ischemic cerebrovascular events in T2DM. Observed benefits were significantly higher in patients with shorter T2DM duration and higher eGFR.PMID:36800286 | DOI:10.1210/clinem/dgad076
Source: The Journal of Clinical Endocrinology and Metabolism - February 17, 2023 Category: Endocrinology Authors: Mainak Banerjee Rimesh Pal Satinath Mukhopadhyay Kirthana Nair Source Type: research